Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Profit After Tax rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13549.54%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Per Keros Therapeutics' latest filing, its Profit After Tax stood at -$7.3 million for Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • Keros Therapeutics' Profit After Tax's 5-year high stood at $148.5 million during Q1 2025, with a 5-year trough of -$53.0 million in Q3 2024.
  • For the 5-year period, Keros Therapeutics' Profit After Tax averaged around -$20.7 million, with its median value being -$29.7 million (2022).
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 32821.33% in 2022, then soared by 44432.2% in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' Profit After Tax stood at -$6.9 million in 2021, then crashed by 328.21% to -$29.7 million in 2022, then crashed by 35.42% to -$40.2 million in 2023, then fell by 14.37% to -$46.0 million in 2024, then surged by 84.18% to -$7.3 million in 2025.
  • Its last three reported values are -$7.3 million in Q3 2025, -$30.7 million for Q2 2025, and $148.5 million during Q1 2025.